Navigation Links
Physicians Reconsider Implications of Enhance Trial
Date:2/7/2008

First Impact Report Reveals Shift in Prescribing Patterns As More MDs

Question Clinical Outcomes of Cholesterol-Reducing Drug

NEW YORK, Feb. 7 /PRNewswire/ -- Despite the controversy surrounding the release of the preliminary ENHANCE trial results on January 14, 2008, physicians are less concerned now -- roughly three weeks later -- about the trial results than they were initially, according to a pivotal FirstImpact Report issued today by FirstWord Publishing, publishers of the FirstWord newsletter, the world's leading source of news for the pharmaceutical industry.

The report, FirstImpact: ENHANCE trial results -- physicians evolving reactions, is based on surveys with general practitioners and cardiologists. The ENHANCE clinical trial results showed that Vytorin, a combination of Zetia and Zocor, is no more effective than Zocor in reducing plaque formation in patients with a condition that affects only about 0.2 percent of the population overall.

In the 48 hours after Merck/Schering-Plough released the preliminary results of the ENHANCE clinical trial, 82 percent of surveyed physicians responded that the results would have an impact on their prescribing decisions. A follow-up survey conducted by FirstImpact Reports on January 31 showed that this impact had decreased to 60 percent. Nonetheless, the FirstImpact survey also found that a large group of physicians continued to have negative reactions to the ENHANCE trial.

"There has been considerable speculation about the potential shifts in prescriptions of Vytorin and Zetia as a result of the ENHANCE trial results. But ultimately, it is the attitudes and treatment intentions of practicing physicians that determine how significantly prescriptions for these products will continue to be affected by the fallout of the ENHANCE trial," said Dominique Balas, president of FirstImpact Reports. She continues, "Our research found that while physicians' prescribing intentions have stabilized, some physicians surveyed by FirstImpact are still planning to switch patients away from Vytorin to therapies such as generic Zocor, Crestor, and Lipitor."

"FirstImpact Reports recruits physicians from the P\S\L Group Healthcare Advisory Board, a community of over 400,000 physicians around the world. For the initial survey, FirstImpact was able to immediately interview 100 US-based physicians within 48 hours following the release of the ENHANCE trial results to gauge their initial reactions to this breaking news," explains Balas. "Two weeks later we conducted a follow-up survey with an additional 120 physicians. FirstImpact Reports are able to immediately measure physicians' reactions to news events because we have unique access to a proprietary panel of over 400, 000 physicians world-wide."

The FirstImpact: ENHANCE trial results - physicians evolving reactions report can be ordered online at http://www.firstwordplus.com/FirstImpactReports/index_vytorin_2.jsp.

About FirstImpact Reports

FirstImpact Reports measure the impact of important medical news on the attitudes and prescribing intentions of practicing physicians, based on market research with physicians. FirstImpact Reports are for industry professionals who need to immediately understand the impact of breaking news.

For more information about this report or other FirstImpact Reports contact Dominique Balas at (514) 938-5480 or by email at info@firstimpactreports.com. FirstImpact Reports is located at 24 West 40th Street, Suite 950, New York, NY, 10018.

CONTACT: Julie Laitin (212) 286-2424

Email: jlaitin@julielaitin.com


'/>"/>
SOURCE FirstImpact Reports
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions
6. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
7. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
10. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
11. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer of a ... Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South Africa. By ... to a patient’s remote health progress, empowering the patient to take direct responsibility for ...
(Date:4/26/2017)... ... ... RawTrition now brings you BioEnergy which is a powder capsule whole food ... RawTrition is taking nutrients to the next level! The superfoods in RawTrition's BioEnergy ... (unlike the synthetically made options that are on the market). , Founder of RawTrition, ...
(Date:4/25/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically ... aging, and minimize the appearance of pores – all with minimal downtime and ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... and HR decision-makers are preparing for how his administration could impact the employee ... insight into what changes are most likely to make it through Congress. His ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... rely on contracted partners to help with process innovation in drug formulation and ... formulation experience along with state-of-the-art analytical equipment in support of their development and ...
Breaking Medicine News(10 mins):